+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07572006

Phase 1 Study of Oral JNJ-95804306 for Relapsed or Refractory Blood Cancers Evaluating Safety, Dose, and Anti-Tumor Activity

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

320

Participants Needed

19

Research Sites

175 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating JNJ-95804306, a drug being studied for safety, tolerability, and anti-tumor activity in adults with relapsed or refractory hematological malignancies, including acute myeloid leukemia AML, high-risk myelodysplastic syndromes MDS, chronic lymphocytic leukemia CLL, small lymphocytic lymphoma SLL, and non-Hodgkin lymphoma NHL. The study is divided into two parts Part 1 focuses on dose escalation to find the recommended phase 2 dose RP2D, and Part 2 expands the dose to further assess safety and anti-tumor effects. The trial is sponsored by Janssen Research & Development, LLC and is a phase 1 interventional study. Participants in Part 1 receive JNJ-95804306 either alone or combined with standard of care SoC therapies depending on their specific cancer type and location. For AMLHR-MDS and CLLSLLNHL groups outside the US, treatments include JNJ-95804306 monotherapy or in addition to SoC therapies, administered orally or subcutaneouslyintravenously as appropriate. In US sites, only JNJ-95804306 monotherapy is given without SoC. Part 2 follows with participants receiving the determined RP2D regimens, maintaining the same treatment assignments as Part 1. Throughout the study, participants undergo regular monitoring for dose-limiting toxicities and adverse events for up to 6 years and 5 months. Researchers measure drug levels in the blood, treatment response rates such as complete and overall responses across different malignancies, and duration and time to response. Participants are also assessed for safety and tolerability continuously. The total study period extends up to 6 years and 5 months, with ongoing evaluation of treatment effects and participant health.

CONDITIONS

Brief Title

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here